Evidence map›Paper›PMID 28482130›Full record

Trial reportClinical and translational science2017

Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin.

J P Kitzmiller, J A Luzum, A Dauki, R M Krauss, M W Medina

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021
    Review
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

J P KitzmillerCenter for Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
J A LuzumCollege of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
A DaukiCenter for Pharmacogenomics, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
R M KraussChildren's Hospital Oakland Research Institute, Oakland, California, USA.
M W MedinaChildren's Hospital Oakland Research Institute, Oakland, California, USA.
The Ohio State University · USUniversity of Michigan–Ann Arbor · US

Funding

Pharmacogenomics of Statin TherapyP50GM115318 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REUE, KAREN · 2015 to 2019
$14.0M
Pharmacogenomics and Risk of Cardiovascular DiseaseU19HL069757 · NHLBI · CHILDREN'S HOSPITAL & RES CTR AT OAKLAND · PI KRAUSS, RONALD M · 2010 to 2014
$12.8M
Expression Genetics in Drug TherapyU01GM092655 · NIGMS · OHIO STATE UNIVERSITY · PI SADEE, WOLFGANG · 2010 to 2014
$8.6M
Statin Pharmacogenomics: A multi-gene PK-PD modeling approachK23GM100372 · NIGMS · OHIO STATE UNIVERSITY · PI KITZMILLER, JOSEPH PAUL · 2011 to 2015
$955k
American Heart Association-American Stroke Association 14POST20100054NHLBI NIH HHS L30 HL110279NHLBI NIH HHS U19 HL069757NIGMS NIH HHS K23 GM100372NIGMS NIH HHS P50 GM115318NIGMS NIH HHS U01 GM092655NIMHD NIH HHS L32 MD006365
6 · The paper itself

Abstract

Cholesterol-lowering response to 40 mg simvastatin daily for 6 weeks was examined for associations with common genetic polymorphisms in key genes affecting simvastatin metabolism (CYP3A4 and CYP3A5) and transport (SLCO1B1). In white people (n = 608), SLCO1B1 521C was associated with lesser reductions of total and low-density lipoprotein cholesterol. Associations between SLCO1B1 521C and cholesterol response were not detected in African Americans (n = 333). Associations between CYP3A4*22 or CYP3A5*3 and cholesterol response were not detected in either race, and no significant race-gene or gene-gene interactions were detected. As several of the analyses may have been underpowered (especially the analyses in the African American cohort), the findings not suggesting an association should not be considered conclusive and warrant further investigation. The finding regarding SLCO1B1 521C in whites was consistent with several previous reports. SLCO1B1 521C resulted in a diminished cholesterol-lowering response, but a marginal effect size limits utility for predicting simvastatin response.

Indexed as

Genetic Association StudiesCholesterolCytochrome P-450 CYP3AFemaleHumansLiver-Specific Organic Anion Transporter 1MaleMiddle AgedPolymorphism, Single NucleotideSimvastatinCholesterolCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3ALiver-Specific Organic Anion Transporter 1SimvastatinSLCO1B1 protein, human

Identifiers

PMID28482130
PMCPMC5421731
OpenAlexW2547425061

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.